Skip to content
Screener

Rapport Therapeutics, Inc. RAPP Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$0-100%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$5.39M-26.1%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$1M+59.9%
Biohaven logo
BiohavenBHVN
$43.4M+22.5%
Septerna, Inc. logo
Septerna, Inc.SEPN
$20.36M-9.8%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
8.5%0.0pp

Other financials

Income statement

See full
Revenue-
Operating income-$60.8M-106%
Net income-$56.6M-112%
EPS (diluted)-$1.19-58.7%

Balance sheet

See full
Cash & equivalents$63.6M+15.5%
Total debt$10.1M-14.8%
Total equity$422.9M+60.5%
Total assets$459.0M+60.8%

Cash flow

See full
Operating cash flow-$41.5M-65.4%
CapEx$78.0K+255%
Free cash flow-$41.5M-65.5%

Valuation

See full
Market cap$2.25B+332%
Enterprise value$2.2B+360%
P/S112.7×

Profitability

See full
Operating margin-767.6%
Net margin-685.8%
FCF margin-485.7%

Returns & leverage

See full
Return on equity-40%+22.3pp
Debt / equity0.0×
Current ratio15.7×-7.0×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:30 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333862
Line itemJune 30,2026December 31,2025
Prepaid expenses and other current assets10,3817,917
Total current assets446,856498,561
Property and equipment, net2,3372,976
Operating lease right of use asset, net8,7329,909
Other assets1,057985
Total assets$458,982$512,431
Liabilities and Stockholders’ Equity
Current liabilities

Item 1. Financial Statements.

FAQ

What is Rapport Therapeutics, Inc.'s operating lease ROU assets?
Rapport Therapeutics, Inc. (RAPP) reported operating lease ROU assets of $8.73M in Q2 2026.
How has Rapport Therapeutics, Inc.'s operating lease ROU assets changed year-over-year?
Rapport Therapeutics, Inc.'s operating lease ROU assets decreased by 21.0% year-over-year, from $11.05M to $8.73M.
What is the long-term trend for Rapport Therapeutics, Inc.'s operating lease ROU assets?
Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s operating lease ROU assets has grown at a 118.1% compound annual growth rate (CAGR), from $2.08M to $9.91M.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.

Ask your AI about Rapport Therapeutics, Inc.'s operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude